Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 4, 2016
- Accepted in final form May 9, 2016
- First Published June 13, 2016.
Author Disclosures
- Steven L. Salzberg, PhD,
- Florian P. Breitwieser, PhD,
- Anupama Kumar, MBBS,
- Haiping Hao, PhD,
- Peter Burger, MD,
- Fausto J. Rodriguez, MD,
- Michael Lim, MD,
- Alfredo Quiñones-Hinojosa, MD,
- Gary L. Gallia, MD,
- Jeffrey A. Tornheim, MD,
- Michael T. Melia, MD,
- Cynthia L. Sears, MD and
- Carlos A. Pardo, MD
- Steven L. Salzberg, PhD,
NONE
NONE
NONE
Associate Editor, Editorial Board member, or Editorial Advisory Board member for the following journals: Genome Biology, PeerJ Computer Science, BMC Biology, Biology Direct, Journal of Computational Biology, BMC Genomics, BMC Bioinformatics, Evolutionary Bioinformatics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health, NHGRI, R01 HG006677, PI, 8/7/2015?6/30/2019 National Institutes of Health, NHLBI, R01 HL129239, PI, 07/01/2015?06/30/2018 National Institutes of Health, NIGMS, R01 GM083873, PI, 4/1/2014?3/31/2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Florian P. Breitwieser, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anupama Kumar, MBBS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Haiping Hao, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Burger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fausto J. Rodriguez, MD,
NONE
NONE
NONE
NONE
NONE
Book: Diagnostic Neuropatology, second edition, Elsevier (2016)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Lim, MD,
1. Novartis - DSMB 2. BMS 3. Stryker
NONE
1. Stryker, honoraria and travel 2. BMS, honoraria and travel
NONE
1. Methods patent for the combination of focused radiation and immunotherapy
1. Handbook of Radiosurgery
NONE
1. Stryker 2. BMS
NONE
NONE
1. Neurosurgery - affect potentially number of surgeries performed
1. Stryker - Research Support 2. BMS - Research Support 3. Aegenus - Research Support 4. CellDex- Research Support 5. Arbor - Research Support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alfredo Quiñones-Hinojosa, MD,
NONE
NONE
Speaker honoraria and travel funding paid from commercial entities Speak Inc. and American Program Bureau, Inc.
Cancer Today, Editorial Advisory Board, 2015-Present
1. NKCC1-pcDNA3-GFP. Quinones-Hinojosa A, Aprhys C, Garzon-Muvdi T. JHU Ref. #C12074 2. Microfluid Assay for the Determination of Tumor Cell Metastatic Propensity. Konstantopoulos K, Paul C, Quinones-Hinojosa A, Kontrogianni-Konstantopoulos. JHU UMSOM Ref#C12511 3. A Novel, High-throughput, Nanotopographic Platform for Screening Cell Migratory Behavior. Christopher Smith, Andre Levchenko, Deok-Ho Kim, Quinones-Hinojosa A. JHU Ref. #C12838. PCT application number PCT/US2015/019692. 4.Quantitative Tissue Property Mapping for Real Time Tumor Detection and Interventional Guidance Li X, Chaichana K, Kut C, Mcveigh E, Quinones-Hinojosa A, Xi J. JHU Ref. #C12934. PCT application number PCT/US15/22432. 5. Nanoparticle Modification of Human Adipose-derived Mesenchymal Stem Cells for Brain Cancer and Other Neurological Diseases Quinones-Hinojosa A, Green J. JHU Ref. #C13152 6. Therapeutic Nanofiber Hydrogels for Local Treatment of Brain-Related Diseases. Cui H, Quinones-Hinojosa A. JHU Ref. #C13285 7. Methods for phenotypic classification of cells based on migratory behavior. Kilic O, Schiapparelli P, Quinones-Hinojosa A, Levchenko A. Ref. #C13721 8.Use of AGX/UAP Inhibitors to Inhibit Flux Through the Hexosamine Biosynthetic Pathway. Saeui C, Shah S, Quinones-Hinojosa A, Yarema K. Ref# C13122 9.Self-Assembling Verteporfin amphiphiles (SAVA) for local brain cancer therapy. Shah S, Martinez-Gutierrez JC, Ruiz-Valls A, Lin R, Cui H, Quinones-Hinojosa A. Ref# C13797. 10.Predicting brain tumor patient prognosis. Konstantopoulos K, Paul C, Martinez-Gutierrez JC, Ruiz-Valls A, Sheng Wong B, Yankaskas, Quinones-Hinojosa A. JHU Ref#C13906 11.NAAG is an indicator of clinical prognosis for glioblastoma Slusher B, Poore B, Lee A, Shah S, Quinones-Hinojosa A. JHU Ref# C14019
1. Quinones-Hinojosa A, (chief ed), Schmidek and Sweet Operative Neurosurgical Techniques, 6e. (eds). Elsevier, 2012. 2. Quinones-Hinojosa A, Eichler M. Becoming Dr Q: My Journey from Migrant Farm Worker to Brain Surgeon. UC Press, 2011. 3. Quinones-Hinojosa A, Eichler M. Dr. Q: La Historia de Como un Jornalero Migrante se Convirtio en Neurocirujano. LID Espanol, 2013. 4. Quinones-Hinojosa A and Raza S., Controversies in Neuro-Oncology: Best Evidence Medicine for Brain Tumor Surgery. Thieme, 2013. 5. Oscar Gonzalez-Perez, Jose M. Garcia-Verdugo, Quinones-Hinojosa A, Sonia Luquin, Graciela Gudino-Cabrera, and Rocio E. Gonzalez-Castaneda (eds). ?Neural Stem Cells in the Adult Brain: From Benchside to Clinic? Stem Cells International Volume 2012. 6. Boahene K and Qui?ones-Hinojosa A. Minimal access skull base surgery: open and endoscopic assisted approaches. 1st edition. Ed. by Boahene and Qui?ones-Hinojosa. India: Jaypee Brothers Medical Publishers (P) LTD. 2016.
NONE
1. Stryker 2. Integra
1. Speak, Inc. 2. American Program Bureau, Inc.
NONE
NONE
1. Stryker 2. Integra
1. NIH, R01NS070024, Principal Investigator,8/1/2010 - 7/31/2015 2. NIH, Principal Investigator, 8/1/2015 - 7/31/2020 3. NIH, R01CA183827, P.I., 5/1/2015 - 4/31/2020 4. NIH/NCI, R01EB016721, Co-investigator, 1/1/2013 ? 12/31/20175. NIH/NCI, R01 CA166171, Co-investigator, 2/5/2013 - 1/31/2018 6. NIH/NCI, R01 CA166171, Co-investigator, 1/1/2011 - 6/31/2016
1. Johns Hopkins University
1. JHU Coulter Foundation 2. Maryland Stem Cell Research Fund (TEDCO) 3. Maryland Biotechnology Development Award 4. Allegheny Health Network-Johns Hopkins Cancer Research Fund
NONE
NONE
NONE
NONE
NONE
NONE
- Gary L. Gallia, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Chordoma Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey A. Tornheim, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael T. Melia, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am a co-investigator for hepatitis C clinical trials conducted at my institution. Funding for these studies has been paid (by Merck, Sharpe & Dohme; Janssen; Gilead; Bristol-Myers Squibb; and AbbVie) to my institution.
12/1/10-present?A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut? Sexually Transmitted Infections Clinical Trials NIH DMID HHSN266200400074C NIAID Total directs TBD; in excess of $10,000,000 PI: Andrea Cox Co-Investigator, effort 10%; A clinical trial of a novel prophylactic HCV vaccine in subjects at risk for HCV infection in which the immune response to the vaccine and correlates of protective immunity will be assessed.10/1/14 ? 9/30/18 ?Maryland Community Based Program to Test and Cure Hepatitis C? PS14-1413 CDC/MDHMH Total directs ~$1,200,000; JHU budget $347,383 per year PI: David Thomas (JHU), Lucy Wilson (MDHMH). (DHMH is the award recipient; JHU is a sub-recipient.) Co-Investigator, effort: 10%; A program designed to strengthen health care capacity to diagnose and cure hepatitis C virus (HCV) infection through implementation of a package of services in a target population with HCV-related health disparities.
7/1/15-12/31/16 The Johns Hopkins School of Medicine Institute for Excellence in Education $50,000 Principal investigator, 10% effort
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cynthia L. Sears, MD and
NONE
NONE
NONE
Clinical Infectious Diseases, Associate Editor, 2001-present
Biofilms in colon cancer as diagnostic approach to identify individuals at risk for colon cancer.
UP-to-Date, reviewer for infectious diseases topics, 2010 to present
NONE
NONE
NONE
NONE
NONE
NONE
1. R01CA179440, NIH, PI, 07/01/13-04/30/17 2. P30AI094189, NIH, project leader, 08/15/14-04/30/16 3. R01ES011858-23A1, NIH/NCI, co-investigator, 09/19/14-05/31/19 4. P30DK089502, NIH, co-investigator, 06/01/11-05/31/16 5. P50CA062924, NIH, project leader, 10/01/15-08/31/16 6. R01CA151393, NIH/NCI, PI, 09/02/10 ? 07/31/15 7. R01CA151325, NIH/NCI, PI, 7/06/10 ? 04/30/15
1. Johns HOpkins Medicine/Applied Physics Laboratory 2. Johns HOpkins SIIME Award
1. Institut Merieux
NONE
NONE
NONE
NONE
NONE
NONE
- Carlos A. Pardo, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Accorda Pharmaceuticals, Clinical Trial, Co-investigator 2012-2014
NIH/NINDS R21NS076381, Role: Principal Investigator, 2012-2015 NIH/NIMH R01NS055628, Role: Principal investigator, 2008-2014 NIH/NINDS R21TW0009741, Role: Co-investigator 2013-2015 NIH-NIMH P30MH075673, Role: Co-Investigator 2005-2016
NONE
Bart McLean Fund for Neuroimmunology Research-Project Restore
NONE
NONE
NONE
NONE
NONE
NONE
- From the Center for Computational Biology, McKusick-Nathans Institute of Genetic Medicine (S.L.S., F.P.B.), Department of Neurology (A.K., C.A.P.), Deep Sequencing and Microarray Core (H.H.), and Departments of Pathology (P.B., F.J.R., C.A.P.), Neurosurgery (M.L., A.Q.-H., G.L.G.), and Medicine (J.A.T., M.T.M., C.L.S.), School of Medicine, and Departments of Biomedical Engineering, Computer Science, and Biostatistics (S.L.S.), Johns Hopkins University, Baltimore, MD.
- Correspondence to Dr. Pardo: cpardov1{at}jhmi.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.